Concepedia

Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse

Andrew Kent, Marc Schwartz, Christine M. McMahon, Maria L. Amaya, Clayton A. Smith, Jennifer Tobin, Kelsey Marciano, Rebecca Rezac, Grace Bosma, Daniel A. Pollyea,

Bone Marrow Transplantation · 2023 · 41 citations · 32 references

DOI

Concepts

References

32

BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

Eleni D. Lagadinou, Alexander Sach, Kevin P. Callahan et al. · Cell stem cell · 2013 · 1.4K citations · Full text

, , +12

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri et al. · Cancer Discovery · 2016 · 1.1K citations · Full text

, , +17

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

Daniel A. Pollyea, Brett M. Stevens, Courtney L. Jones et al. · Nature Medicine · 2018 · 797 citations · Full text

, , +12

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i>–Internal Tandem Duplication Mutation (SORMAIN)

Andreas Burchert, Gesine Bug, Lea Fritz et al. · Journal of Clinical Oncology · 2020 · 551 citations · Full text

, , +15

Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis

Haesook T. Kim · Clinical Cancer Research · 2007 · 507 citations

, , +9